Neuronetics earnings date
Neuronetics (NRC) Q3 2026 Earnings Report
DE:NRC Q3 2026 EPS Results
- Actual EPS
- -EUR 0.02
- Consensus EPS
- -EUR 0.07
- Beat/Miss
- Beat by +EUR 0.05
- One Year Ago EPS
- -EUR 0.12
DE:NRC Q3 2026 Revenue Results
- Actual Revenue
- EUR 38.07M
- Expected Revenue
- EUR 36.97M
- Beat/Miss
- Beat by +EUR 1.10M
- YoY Revenue Growth
- +12.51%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- Before Open
- Conference Call
- Wednesday, November 4, 2026
Neuronetics's next earnings date is estimated for March 9, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was predominantly positive. Management reported double-digit total and Greenbrook revenue growth, record NeuroStar system sales, higher gross margin, lower operating expenses, positive adjusted EBITDA, improved cash flow, and better full-year margin, expense, and cash-flow guidance. The main challenges were declining Sessions revenue, uneven clinic occupancy, a continued full-year cash-flow deficit, lower cash than at year-end 2025, and a remaining net loss.
For the full year 2026, Neuronetics expects total revenue between $160 million and $164 million, gross margin between 49-50%, operating expenses, excluding stock based compensation of between $89 million and $92 million with estimated stock based compensation of $3.5 million, operating expenses between $92.5 million and $95.5 million, and cash flow from operating and investing in the range of negative $10 million to negative $12 million; it continues to target limited to no net cash utilization from operating and investing in the second half of the year. NeuroStar revenue mix is expected to be weighed slightly towards NeuroStar capital in the fourth quarter, session revenue is expected to continue to trend slightly downwards, and the company expects to yield higher overall net growth in 2027 and beyond. Greenbrook plans to add 8 reps to its already in base of 20, taking the team to 28 by sometime in Q1, with the new reps expected to be fully ramped up and contribute meaningfully by mid 27, while Compass expects a launch in the first half of 27.
- Quarterly Revenue GrowthThird-quarter total revenue was approximately $42 million, up 12.5% from $37.3 million in the prior-year quarter, driven primarily by higher Greenbrook revenue.
- Record NeuroStar System SalesNeuroStar worldwide revenue was $15.8 million, up approximately 2% year over year. Capital equipment revenue delivered a record quarter with strong double-digit year-over-year performance, supported by the expanded go-to-market strategy and including a recently awarded sole-source agreement with a large national player.
- Broader NeuroStar Market ReachManagement said the new go-to-market approach enabled placements with customers the company could not previously compete for and is expected to support higher overall net growth in 2027 and beyond.
- NeuroStar Treatment-Session DifferentiationManagement said the treatment-session model remains a differentiator for emerging TMS practices, with NeuroStar customers performing almost twice as many treatments per chair as the competitive landscape.
- Growth Among Existing Session CustomersAlthough overall Sessions revenue declined, session volume grew modestly among customers that were already customers a year ago.
- Accelerated TMS Protocol SubmissionIn August, Neuronetics submitted a 510(k) application to the FDA for an accelerated TMS protocol, which was under review. Management said condensed protocols could expand access to TMS for some patients.
- Real-World Evidence on Treatment GapsA TMS Journal publication analyzed more than 6.4 thousand patients treated with NeuroStar. Approximately 15% completed treatment with no gaps, while 85% missed one or more scheduled treatment days; the analysis found no statistically significant difference in outcomes between patients with and without a treatment gap, and concluded that missing treatment for up to 13 days did not reduce effectiveness.
- Wave Neuroscience Distribution AgreementNeuronetics signed a distribution agreement with Wave Neuroscience to integrate its MeRT system with NeuroStar. MeRT uses EEG data to personalize TMS protocols and received FDA clearance in June for treating adults with PTSD, with a 68% remission rate in its pivotal trial. Management said approximately 9 million U.S. adults experience PTSD annually, with an estimated 4+ million seeking treatment, and plans to seek clearance to add NeuroStar as a compatible TMS system.
- TrackStar and AdvancedMD EHR IntegrationNeuronetics announced an integration between TrackStar and AdvancedMD, a cloud-based EHR, practice-management, and revenue-cycle platform serving more than 65 thousand practitioners across 13 thousand independent practices. The integration was expected to become available in the fourth quarter and is designed to allow treatment data, schedules, clinical records, notes, claims, and revenue-cycle information to flow through the same system.
- Greenbrook Revenue ExpansionGreenbrook revenue was approximately $26 million, or $26.2 million according to the detailed financial discussion, up 20.1% year over year. Growth reflected revenue-cycle-management gains and growth in Spravato, which management described as more durable because patients can continue into a maintenance phase.
- Revenue-Cycle Management ProgressGreenbrook's revenue-cycle work produced better patient qualification, cleaner claims, and more efficient collections, helping convert more billed dollars to cash. Management said most of the improvements were durable and that additional improvement remained available.
- Skypoint AI Coding OptimizationGreenbrook began deploying Skypoint, an AI-enabled coding optimization tool. Management said the workflow change produced a low double-digit improvement in collections during the first month, while some back-office headcount was reduced and redirected to other roles.
- Improved Gross MarginThird-quarter gross margin increased to 52.2% from 45.9% in the prior-year quarter. Management attributed the improvement to the new NeuroStar go-to-market strategy, the mix of capital and lease units, and improved revenue-cycle management within Greenbrook.
- Lower Operating Expenses and Improved Operating ResultOperating expenses declined 12.6% to $21.3 million from $24.4 million. Income from operations improved to $5 million from a $7.3 million loss in the prior-year quarter, an improvement of $7.9 million.
- Improved Net Loss and Adjusted EBITDANet loss attributable to Neuronetics stockholders narrowed to $1.7 million, or $0.02 per share, from a $9 million loss, or $0.13 per share. Adjusted EBITDA improved to positive $1.9 million from negative $4.7 million, a $6.6 million improvement.
- Positive Third-Quarter Operating and Investing Cash FlowCash provided by operating and investing activities was $800 thousand in the third quarter, compared with negative cash flow of $900 thousand in the prior-year quarter.
- Improved Full-Year Expense and Cash-Flow GuidanceFull-year 2026 revenue guidance remained $160 million to $164 million. Gross-margin guidance increased to 49%-50% from 48%-50%; operating expenses excluding stock-based compensation were revised to $89 million-$92 million from $91 million-$96 million; total operating expenses were revised to $92.5 million-$95.5 million from $95 million-$100 million; and operating and investing cash flow guidance improved to negative $10 million to negative $12 million from negative $10.5 million to negative $14.5 million. Management continued to target limited to no net cash utilization from operating and investing activities in the second half of the year.
- Greenbrook Sales-Team ReallocationThe company plans to shift a portion of direct-to-consumer advertising spending toward the Greenbrook field sales team because field sales personnel were delivering a better return and more control over patient acquisition cost and yield. Management plans to add 8 representatives to the existing 20, reaching 28 by sometime in Q1, without increasing overall sales and marketing expense; the new representatives are expected to be fully ramped and contribute meaningfully by mid-2027.
- Spravato Network and GrowthGreenbrook operates 84 Spravato clinics. Management reported double-digit Spravato growth and said the maintenance phase of treatment makes the business durable as patients continue within the network.
- Compass Pathways CollaborationNeuronetics continued preparing with Compass Pathways for the anticipated commercial launch of COMP360 for treatment-resistant depression. Compass reported 52-week Phase III COMP-005 data showing that an additional dose extended the benefit out to one year, expected to complete its FDA submission in two weeks, and expected a launch in the first half of 2027.
- Readiness for Future Interventional Psychiatry ServicesManagement said Greenbrook's existing Spravato platform provides in-office drug administration, monitoring, REMS programs, trained clinical staff, benefits investigation, and prior-authorization infrastructure that could support COMP360. Greenbrook's experience, scale, and available capacity were described as positioning the company to provide a broader menu of interventional psychiatry options.
- Capital and Lease MixMore than half of NeuroStar units sold in the third quarter were capital or lease units. Management said these units were new systems rather than conversions of existing session customers, carried a higher average selling price, and were favorable for gross margin.
DE:NRC Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 09, 2027 | 2026 (Q4) | -0.07- | -0.09 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | -0.07-0.02 | -0.12 | 84.62% (+0.10) | |
| Aug 11, 2026 | 2026 (Q2) | -0.11-0.05 | -0.14 | 66.67% (+0.09) | |
| May 05, 2026 | 2026 (Q1) | -0.16-0.15 | -0.19 | 23.81% (+0.05) | |
| Mar 17, 2026 | 2025 (Q4) | -0.10-0.09 | -0.3 | 69.70% (+0.21) | |
| Nov 04, 2025 | 2025 (Q3) | -0.11-0.12 | -0.4 | 70.45% (+0.28) | |
| Aug 05, 2025 | 2025 (Q2) | -0.07-0.14 | -0.3 | 54.55% (+0.16) | |
| May 06, 2025 | 2025 (Q1) | -0.11-0.19 | -0.24 | 22.22% (+0.05) | |
| Mar 04, 2025 | 2024 (Q4) | -0.22-0.30 | -0.17 | -73.68% (-0.13) | |
| Nov 12, 2024 | 2024 (Q3) | -0.21-0.40 | -0.3 | -33.33% (-0.10) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


